Patient characteristics by treatment group for study completers
| Parameter | 0.4 mg | 40 mg | placebo |
|---|---|---|---|
| Patients (n) | 3 | 7 | 2 |
| Female:male | 2:1 | 6:1 | 1:1 |
| Median age in years (range) | 72.3 (70–76) | 62.6 (36–72) | 68.0 (63–73) |
| Median disease duration in years (range) | 11.3 (1–22) | 11.4 (3–20) | 13.3 (8–17) |
| Current DMARD use | 3 | 6 | 2 |
| Methotrexate | 1 | 4 | 1 |
| Sulphasalazine | 0 | 2 | 1 |
| Azathioprine | 1 | 0 | 0 |
| Cyclosporin | 1 | 0 | 0 |
| Current prednisolone use | 1 | 1 | 1 |
| Baseline median knee circumference (cm) (range) | 38.6 (37.6–39.5.) | 36.5 (36.1–38.9) | 38.2 (35.4–41.0) |
| End median knee circumference (cm) (range) | 38.4 (35.8–41.0) | 37.1 (35.8–40.1) | 38.6 (35.4–41.8) |
| Baseline median CRP (g/dl) (range) | 8.5 (3.4–45.1) | 27.5 (6.2–79.6) | 66.1 (40.1–92.0) |
| End median CRP (g/dl) (range) | 35.4 (15.0–52.2) | 24.0 (8.4–102) | 50.2 (8.4–92.0) |
| Intra-articular corticosteroid requirement at 18 months follow up | 1 | 0 | 2 |